Alain Bouchard, MD
Cardiovascular Disease · Birmingham, ALNPI 1659336790
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Pfizer at 52.1% of the total. Reporting peaked in 2022 at $6,328 and has fallen 73.2% since, to $1,694 in 2025.
Across 142 payments — averaging $91.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$7K
- Novartis$2K
- Boston Scientific$2K
- Janssen Research & Development, LLC$1K
- E.r. Squibb & Sons, L.L.C.$229
- Amgen$228
- plus $1K from 23 others
Across 79 payments — averaging $23,812 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$901K
- Janssen Research & Development, LLC$658K
- Endotronix, Inc.$181K
- Amgen$132K
- Abbott$9K
- Boston Scientific$1K
What the payments were for
- Speaking & faculty fees$5,16040%
- Travel & lodging$3,30325%
- Food & beverage$4,54035%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 20 | $6,785 |
| Novartis | 43 | $1,713 |
| Boston Scientific | 7 | $1,698 |
| Janssen Research & Development, LLC | 9 | $1,142 |
| E.r. Squibb & Sons, L.L.C. | 11 | $229 |
| Amgen | 6 | $228 |
| Abbott | 3 | $188 |
| Edwards Lifesciences | 2 | $167 |
| Boehringer Ingelheim | 6 | $132 |
| Medtronic | 1 | $91 |
| Novo Nordisk | 3 | $70 |
| Amarin Pharma, Inc. | 4 | $59 |
| Sanofi-aventis U.S. LLC | 3 | $58 |
| Merck | 1 | $55 |
| Bayer | 3 | $51 |
| Johnson & Johnson | 3 | $46 |
| Scpharmaceuticals Inc. | 3 | $43 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $40 |
| Lantheus Medical Imaging, Inc. | 1 | $37 |
| AstraZeneca | 2 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Stryker | 1 | $23 |
| Lundbeck LLC | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $18 |
| Cardiovascular Systems Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| United Therapeutics Corporation | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORGOVYX$6,006
- Watchman$1,543
- ELIQUIS$343
- SAPIEN 3 Ultra RESILIA$154
- WATCHMAN Access System$127
- Repatha$122
- VYNDAQEL$121
- Xience Sierra Coronary Stent System$116
- ENTRESTO$103
How this compares
$13,021 in reported general payments places this provider in the 85th percentile of 292 cardiovascular disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 1,018 | $787,753 |
| EliquisApixaban | 745 | $586,056 |
| EntrestoSacubitril/Valsartan | 380 | $365,587 |
| OzempicSemaglutide | 101 | $100,436 |
| FarxigaDapagliflozin Propanediol | 104 | $69,090 |
| XareltoRivaroxaban | 44 | $44,828 |
| Repatha SureclickEvolocumab | 42 | $35,252 |
| MultaqDronedarone Hcl | 22 | $28,865 |
| WegovySemaglutide | 16 | $26,983 |
| Ranolazine ErRanolazine | 291 | $26,779 |
| MounjaroTirzepatide | 20 | $20,464 |
| Metoprolol Succinate | 1,084 | $19,896 |
| Rosuvastatin Calcium | 789 | $16,547 |
| RybelsusSemaglutide | 16 | $15,912 |
| VascepaIcosapent Ethyl | 21 | $11,598 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $132 | $787,7531,018 claims |
| PfizerEliquis | $6,785 | $586,056745 claims |
| NovartisEntresto | $1,713 | $365,587380 claims |
| Novo NordiskOzempic, Wegovy, Rybelsus | $70 | $143,331133 claims |
| AstraZenecaFarxiga | $30 | $69,090104 claims |
| Johnson & JohnsonXarelto | $46 | $44,82844 claims |
| Sanofi-aventis U.S. LLCMultaq | $58 | $28,86522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 292 cardiovascular disease providers in Alabama.
Other cardiovascular disease in Birmingham
- Vikram AroraBirmingham$271K
- Jason ThompsonBirmingham$248K
- Michael WilenskyBirmingham$241K
- Mustafa AhmedBirmingham$218K
- Frederick GaskinBirmingham$115K
- Pankaj AroraBirmingham$83K
- Thomas CawthonBirmingham$54K
- Weihan ChenBirmingham$51K
- Farrell MendelsohnBirmingham$51K
- Charles MooreBirmingham$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.